How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

for the treatment of Attention Deficit Disorder) with the exception of low dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over-the-counter dietary supplements or herbs with psychoactive, appetite or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; cholestyramine, cholestypol, Depo (...) Overweight Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day Drug: Placebo Behavioral: Ancillary therapy Phase 3 Detailed Description: Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of 2 doses of the combination

2007 Clinical Trials

262. A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities Received the following excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer, anticonvulsant agents, and agents for the treatment of attention deficit disorder) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any (...) Mellitus, Type 2 Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day Drug: Placebo Behavioral: Ancillary therapy Phase 3 Detailed Description: Optimal care of patients with diabetes mellitus includes vigorous and persistent efforts to achieve physiologic control of blood glucose as well as other often associated conditions including hypertension, dyslipidemia and excess weight. Pharmacologic interventions for the treatment of obesity in type 2 diabetes have shown significant reductions in HbA1c. Two

2007 Clinical Trials

263. A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

, or atrial or ventricular dysrhythmia or significant conduction abnormalities Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents or agents for the treatment of attention deficit disorder) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss (...) : November 21, 2014 Sponsor: Orexigen Therapeutics, Inc Information provided by (Responsible Party): Orexigen Therapeutics, Inc Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity. Condition or disease Intervention/treatment Phase Obesity Overweight Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day Drug: Placebo Behavioral: Ancillary therapy Phase 3

2007 Clinical Trials

264. Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

Enzyme CYP2B6 CYP2E1 Pharmacogenetics Pharmacokinetics Pharmacodynamics Boston Tufts University Additional relevant MeSH terms: Layout table for MeSH terms Depression Attention Deficit Disorder with Hyperactivity Alcohol Drinking Behavioral Symptoms Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Drinking Behavior Bupropion Ethanol Chlorzoxazone Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Dopamine Uptake (...) Attention Deficit Disorder Drug: Bupropion Drug: Chlorzoxazone Drug: Ethanol Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 80 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Human CYP2B6: Induction by Ethanol and Polymorphisms Study Start Date : December 2005 Actual Primary Completion Date : April 2008 Actual

2006 Clinical Trials

265. Bupropion Treatment for Youth Smoking Cessation

History or current diagnosis of panic disorder, psychosis, bipolar disorder, or eating disorder History of abuse or dependence on alcohol or other recreational or prescription drugs in the three months preceding the study Current evidence of clinical depression or Attention Deficit/Hyperactivity Disorder Use of any psychoactive drug and/or any type of antidepressant with in four weeks of the treatment phase of the study Predisposition to seizure or tic disorders or a personal history of a seizure (...) Disorders Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Physiological Effects of Drugs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors

2006 Clinical Trials

266. Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder

symptoms in bipolar patients with depression, the treatment of bipolar depression poses unique and challenging therapeutic dilemmas Thus, the identification of appropriate safe and effective treatment strategies for the management of depression in bipolar youth is particularly taxing considering that pediatric mania is predominantly mixed with a strong depressive component. A recent study in our program of bupropion SR in 30 adults with ADHD and Bipolar disorder, treatment with bupropion SR (...) : September 16, 2005 Last Update Posted: July 15, 2011 Last Verified: July 2011 Keywords provided by Massachusetts General Hospital: depression bipolar disorder children bupropion SR Additional relevant MeSH terms: Layout table for MeSH terms Disease Depression Depressive Disorder Bipolar Disorder Depressive Disorder, Major Pathologic Processes Behavioral Symptoms Mood Disorders Mental Disorders Bipolar and Related Disorders Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents

2005 Clinical Trials

267. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. (Abstract)

for PG, the Gambling Severity Assessment Scale, the Clinical Global Impression Improvement and Severity Scales, the Global Assessment Scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Rating Scale, and the Sheehan Disability Scale. Thirty-nine subjects (28 men, 11 women) were randomized to bupropion (n = 18) or placebo (n = 21). The 2 groups were similar on demographic and clinical measures. There were few differences between the treatment groups on any primary (...) Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG). Nondepressed, healthy subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG were randomly assigned to placebo or flexibly dosed bupropion in a 12-week double-blind trial. Outcome measures included the Yale-Brown Obsessive-Compulsive Scale modified

2007 Journal of Clinical Psychopharmacology Controlled trial quality: predicted high

268. Bupropion for the treatment of methamphetamine dependence. Full Text available with Trip Pro

, and level of symptoms of depression). This subgroup analysis showed that bupropion had a significant effect compared to placebo, among male patients who had a lower level of methamphetamine use at baseline (p<0.0001). Comorbid depression and attention-deficit/hyperactivity disorder did not change the outcome. These data suggest that bupropion, in combination with behavioral group therapy, was effective for increasing the number of weeks of abstinence in participants with low-to-moderate methamphetamine (...) factors and comorbid conditions, addiction severity, craving, risk behaviors for HIV, and use of other substances. The generalized estimating equation regression analysis showed that, overall, the difference between bupropion and placebo groups in the probability of a non-use week over the 12-week treatment period was not statistically significant (p=0.09). Mixed model regression was used to allow adjustment for baseline factors in addition to those measured (site, gender, level of baseline use

2008 Neuropsychopharmacology Controlled trial quality: uncertain

269. Steady-state pharmacokinetics of bupropion SR in juvenile patients. (Abstract)

Steady-state pharmacokinetics of bupropion SR in juvenile patients. To examine the steady-state pharmacokinetic properties of bupropion sustained release (SR) and their potential developmental differences in youths.Eleven boys and eight girls aged 11 to 17 years old were prescribed bupropion SR monotherapy for attention-deficit/hyperactivity disorder (n = 16) and/or depressive disorders (n = 16). Bupropion SR was given in morning doses of 100 mg/day (n = 11) or 200 mg/day (n = 8) for 14 days (...) or less, with five subjects studied on both doses. All subjects had blood draws from an intravenous port every 1 to 3 hours for 24 hours after their usual morning doses. Pharmacokinetic variables were determined by noncompartmental and compartmental analyses for bupropion and metabolites, respectively.Bupropion and its metabolites exhibited linear pharmacokinetics. Areas under the concentration curves for the hydroxybupropion, threohydrobupropion, and erythrohydrobupropion were 20, 12, and 2.7 times

2005 Journal of the American Academy of Child and Adolescent Psychiatry

270. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. (Abstract)

Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. The purpose of this double-blind, three-arm, 12-week trial was to compare the efficacy of sustained-release methylphenidate or sustained-release bupropion to placebo in treating adult attention deficit hyperactivity disorder (ADHD) symptoms. The randomized sample consisted of 98 methadone-maintained patients who were pre-dominantly male (57%) and 40% Caucasian, 40 (...) % Hispanic and 20% African American. All participants met DSM-IV criteria for adult ADHD, with 53% meeting DSM-IV criteria for cocaine dependence/abuse. In addition to medication and treatment as usual at a methadone program, individuals received weekly individual cognitive behavioral treatment. Other than current employment status, there were no significant demographic differences across the three treatment groups. Seventy percent completed the 12-week trial. There were no differences in retention rate

2006 Drug and alcohol dependence Controlled trial quality: uncertain

271. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Full Text available with Trip Pro

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Increased attention has been given to the alternatives to stimulants in the treatment of attention deficit hyperactivity disorder (ADHD) in both adults and children. This short-term, double-blind trial was designed to evaluate the extended-release form of bupropion in adult subjects meeting DSM-IV and the Utah Diagnostic Criteria for ADHD. Outcome measures were the Clinical Global Impressions-Improvement (CGI-I (...) ) and the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), which assesses adult ADHD symptoms. Outcome (defined by the CGI-I, average WRAADDS scores, or a 50% improvement on the WRAADDS) favored bupropion SR over placebo, but achieved statistical significance on only one, post hoc measure. Other measures showed trends for improvement with bupropion. Given the small size of this study, these findings deserve further exploration.

2005 Neuropsychiatric disease and treatment Controlled trial quality: uncertain

272. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. (Abstract)

An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. Adolescents with conduct disorder (CD) and substance use disorders (SUD) have higher rates of comorbid attention-deficit/hyperactivity disorder (ADHD) than those without CD and SUD. Comorbid ADHD may contribute to more severe SUD. Treatment of ADHD may enhance effective treatment of substance abuse and behavior problems, yet there are few data regarding pharmacological treatment of ADHD (...) in such youths.Pilot data are presented from a 5-week, open-label bupropian trial in 13 nondepressed adolescent boys in a residential treatment program focusing on substance and behavioral treatments. All had diagnoses of ADHD, CD, and SUD. Patients' doses were titrated to a maximum fixed daily dose of 300 mg of bupropion. The Conners Hyperactivity Index and Daydream Attention scores, along with Clinical Global Impressions Severity of Illness (CGI-S) ratings, were obtained at baseline and at the fifth week

1998 Journal of the American Academy of Child and Adolescent Psychiatry

273. Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder

and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel’s final revisions. Conclusions Attention deficit hyperactivity disorder or ADHD is a commonly diagnosed behavioral disorder of childhood that represents a costly major public health problem. Children with ADHD have pronounced (...) . Finally, after years of clinical research and experience with ADHD, our knowledge about the cause or causes of ADHD remain largely speculative. Consequently, we have no docu­ mented strategies for the prevention of ADHD. 3 Introduction Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed behavioral disorder of childhood, estimated to affect 3 to 5 percent of school-age children. Its core symptoms include developmentally inappropriate levels of attention, concentration

1998 NIH Consensus Statements

274. The use of antidepressants to treat attention deficit hyperactivity disorder in adults

, in adults with ADHD. Bibliographic details Maidment I D. The use of antidepressants to treat attention deficit hyperactivity disorder in adults. Journal of Psychopharmacology 2003; 17(3): 332-333 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Antidepressive Agents /pharmacology /therapeutic use; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity /drug therapy; Bupropion /pharmacology /therapeutic use; Clinical Trials as Topic; Cyclohexanols /pharmacology (...) standard diagnostic criteria to determine the long-term effectiveness. The tentative conclusion follows from the evidence presented, although there were several methodological weaknesses in the conduct of the review. Authors' objectives The author's objective appears to have been to evaluate the use of antidepressants for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. Searching MEDLINE was searched for the year 2002; the search terms were provided. Additional articles were

2003 DARE.

275. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review

Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review Wilens T E, Biederman J, Spencer T J, Prince J Authors' objectives To review the effectiveness and dosing parameters of medication treatment for adult attention deficit/hyperactivity disorder (ADHD). Searching A 'systematic computerised search' was undertaken with search (...) terms including 'hyperactivity', 'hyperkinesis', 'impulsivity', 'attention deficit disorder' and 'attention deficit hyperactivity disorder', cross-referenced with 'adults'. Study selection Study designs of evaluations included in the review Controlled and uncontrolled studies (including retrospective studies) were included. Case reports were excluded unless they contained otherwise unavailable data. Specific interventions included in the review Stimulants (specifically methylphenidate and pemoline

1995 DARE.

276. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder

in the treatment of adults with attention-deficit hyperactivity disorder (ADHD). Searching MEDLINE was searched for English language articles (years and search terms not listed). Reference lists of other pertinent studies were scanned. Study selection Study designs of evaluations included in the review Controlled and uncontrolled, retrospective and prospective studies. Open-label and double blind designs were included. Details of whether studies were controlled, and what the control groups were, were unclear (...) for adults with attention-deficit hyperactivity disorder (ADHD). Recent controlled studies suggest that desipramine (an antidepressant) may be as effective as methylphenidate (a stimulant) for improving symptoms of adult ADHD. Although few good controlled studies exist, the available research suggests that certain antidepressants and stimulants are equally effective for adults with ADHD. Antidepressants may offer a safe first-line treatment for adults with ADHD. CRD commentary There are many details

1999 DARE.

277. Cocaine Abuse and Attention Deficit Disorder

Update Posted: January 12, 2017 Last Verified: November 2016 Keywords provided by National Institute on Drug Abuse (NIDA): cocaine dependence Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Cocaine-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Substance-Related Disorders Chemically-Induced Disorders Bupropion Cocaine Antidepressive Agents, Second (...) (NIDA) Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder Condition or disease Intervention/treatment Phase Cocaine-Related Disorders Drug: Bupropion Not Applicable Detailed Description: To evaluate the safety and efficacy of methylphenidate and bupropion in treating individuals with adult Attention Deficit Disorder. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

1999 Clinical Trials

278. Association of attention-deficit disorder and the dopamine transporter gene. Full Text available with Trip Pro

Association of attention-deficit disorder and the dopamine transporter gene. Attention-deficit hyperactivity disorder (ADHD) has been shown to be familial and heritable, in previous studies. As with most psychiatric disorders, examination of pedigrees has not revealed a consistent Mendelian mode of transmission. The response of ADHD patients to medications that inhibit the dopamine transporter, including methylphenidate, amphetamine, pemoline, and bupropion, led us to consider the dopamine (...) transporter as a primary candidate gene for ADHD. To avoid effects of population stratification and to avoid the problem of classification of relatives with other psychiatric disorders as affected or unaffected, we used the haplotype-based haplotype relative risk (HHRR) method to test for association between a VNTR polymorphism at the dopamine transporter locus (DAT1) and DSM-III-R-diagnosed ADHD (N = 49) and undifferentiated attention-deficit disorder (UADD) (N = 8) in trios composed of father, mother

1995 American Journal of Human Genetics

279. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD)

The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD) The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD) The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD) Smith B H, Waschbusch D A, Willoughby M T, Evans S Authors' objectives To review studies of interventions for adolescents diagnosed (...) with attention-deficit/hyperactivity disorder (ADHD) in order to evaluate the efficacy of the interventions. Searching MEDLINE, ERIC and PsycLIT were searched using the following keywords: 'treatment', 'adolescent', 'teen', 'ADHD', 'hyperactive', 'inattentive', and 'stimulant'. Further studies were identified from references in the review papers. No restrictions on publication language were reported. Study selection Study designs of evaluations included in the review Empirical studies were included. Specific

2000 DARE.

280. Bupropion in children with attention deficit disorder. (Abstract)

Bupropion in children with attention deficit disorder. 2513592 1990 02 08 2013 11 21 0048-5764 25 2 1989 Psychopharmacology bulletin Psychopharmacol Bull Bupropion in children with attention deficit disorder. 198-201 Casat C D CD Pleasants D Z DZ Schroeder D H DH Parler D W DW eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Psychopharmacol Bull 0101123 0048-5764 0 Propiophenones 01ZG3TPX31 Bupropion IM Attention (...) Deficit Disorder with Hyperactivity drug therapy psychology Bupropion Child Double-Blind Method Humans Propiophenones therapeutic use Psychiatric Status Rating Scales Randomized Controlled Trials as Topic 1989 1 1 1989 1 1 0 1 1989 1 1 0 0 ppublish 2513592

1990 Psychopharmacology Bulletin Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>